AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38439783 — intervention group
Group type: COMPARATOR
Intervention: Controls without epilepsy (n=20)
Number of subjects: 40
Study 38439933 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS training with instructor feedback
Number of subjects: 360
Study 38439933 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS training with software-based feedback
Number of subjects: 360
Study 38440046 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based image processing workflow (One-Step PASI framework)
Number of subjects: 2700
Study 38440046 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model performance
Number of subjects: 2700
Study 38440130 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline solution) nasal spray 0.6 mg/mL twice daily (BID)
Number of subjects: 340
Study 38440130 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline solution) nasal spray 0.6 mg/mL BID
Number of subjects: 340
Study 38440130 — intervention group
Group type: COMPARATOR
Intervention: Vehicle nasal spray
Number of subjects: 340
Study 38440179 — intervention group
Group type: EXPERIMENTAL
Intervention: Houtou Jianweiling tablet
Number of subjects: 0
Study 38440179 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38440302 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-bioavailability itraconazole (SUBA-itra)
Number of subjects: 88
Study 38440302 — intervention group
Group type: COMPARATOR
Intervention: Conventional itraconazole (c-itra)
Number of subjects: 88
Study 38440406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) intervention
Number of subjects: 621
Study 38440406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hassles frequency measured in the third trimester
Number of subjects: 621
Study 38440406 — intervention group
Group type: EXPERIMENTAL
Intervention: Uplifts intensity measured in the third trimester
Number of subjects: 621
Study 38440406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hassles intensity measured in the third trimester
Number of subjects: 621
Study 38440406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity ratio of hassles to uplifts reported in the third trimester
Number of subjects: 621
Study 38440406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy experiences at baseline during early to mid-pregnancy
Number of subjects: 621
Study 38440777 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Through Remote Observation and Nutrition Guidance (STRONG) intervention
Number of subjects: 80
Study 38440777 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 38440875 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop recorder (Reveal LINQ)
Number of subjects: 956
Study 38440875 — intervention group
Group type: COMPARATOR
Intervention: Control group (no loop recorder)
Number of subjects: 956
Study 38440889 — intervention group
Group type: EXPERIMENTAL
Intervention: Every Visit (n=339)
Number of subjects: 607
Study 38440889 — intervention group
Group type: COMPARATOR
Intervention: <Every Visit (n=268)
Number of subjects: 607
Study 38441108 — intervention group
Group type: EXPERIMENTAL
Intervention: New devices and techniques for early management of NCTH
Number of subjects: 0
Study 38441108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hemostatic resuscitation
Number of subjects: 0
Study 38441108 — intervention group
Group type: EXPERIMENTAL
Intervention: Control the bleeding source, resuscitate to maintain organ perfusion, and increase resistance against ischemia
Number of subjects: 0
Study 38441437 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0
Study 38441437 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02 + Bortezomib
Number of subjects: 0
Study 38441437 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 0
Study 38441437 — intervention group
Group type: EXPERIMENTAL
Intervention: Knock down of ATM, AMPKα, ULK1, Beclin1 or ATG5
Number of subjects: 0
Study 38441437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined knock down of HDACs1/2/3
Number of subjects: 0
Study 38441576 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin (EV) 1.25 mg/kg plus Pembrolizumab 200 mg
Number of subjects: 121
Study 38441657 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic and open surgery for rectal cancer (part of COLOR II trial)
Number of subjects: 385
Study 38441657 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce fatigue and pain
Number of subjects: 385
Study 38441850 — intervention group
Group type: EXPERIMENTAL
Intervention: AbGn-107 at 1.0 mg/kg every 2 weeks (Q2W)
Number of subjects: 39
Study 38441850 — intervention group
Group type: EXPERIMENTAL
Intervention: AbGn-107
Number of subjects: 39
Study 38441854 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/kg/day cannabidiol (Epidyolex)
Number of subjects: 0
Study 38441897 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTRA-CVD intervention group
Number of subjects: 297
Study 38441897 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 297
Study 38441919 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 2.5 mg + 100 mg placebo
Number of subjects: 36
Study 38441919 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg + 2.5 mg placebo
Number of subjects: 36
Study 38441919 — intervention group
Group type: COMPARATOR
Intervention: Placebo 2.5 mg + 100 mg placebo
Number of subjects: 36
Study 38441919 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (combined with all interventions)
Number of subjects: 36
Study 38441939 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Sprint-Intensity Interval Training (SIT) program, 3 tele-supervised sessions per week, 30 repeated sequences of 4 seconds of maximal arm exercise, with active recovery, warm-up, and cooldown periods (approximately 20 minutes total session).
Number of subjects: 50
Study 38441939 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group continuing habitual activity for 12 weeks.
Number of subjects: 50
Study 38442717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rivaroxaban regimen (HDRR, 20/15 mg)
Number of subjects: 1093
Study 38442717 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rivaroxaban regimen (LDRR, 15/10 mg)
Number of subjects: 1093
Study 38442809 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 1689
Study 38442809 — intervention group
Group type: COMPARATOR
Intervention: Physician-recommended and conventional treatments
Number of subjects: 1689
Study 38443074 — intervention group
Group type: EXPERIMENTAL
Intervention: ds-MCE
Number of subjects: 607
Study 38443074 — intervention group
Group type: COMPARATOR
Intervention: OGD
Number of subjects: 607
Study 38443077 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey measuring the impact of the cardiac condition on specific life domains (e.g., daily activities, social and family relationships, hobbies, sexual life)
Number of subjects: 268
Study 38443077 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire-4 for measuring anxiety and depression symptoms
Number of subjects: 268
Study 38443077 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative content analysis of survey items evaluating experiences and preferences for improvements to the waiting experience
Number of subjects: 268
Study 38443079 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of an e-cigarette starter kit and referral to stop smoking services (SSS)
Number of subjects: 10
Study 38443079 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional panel recommendations for e-cigarette devices
Number of subjects: 10
Study 38443079 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI lay panel feedback on e-cigarette devices
Number of subjects: 10
Study 38443081 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus daily mobile phone text messages with instructions for outdoor walking and functional leg exercises.
Number of subjects: 79
Study 38443081 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 79
Study 38443087 — intervention group
Group type: EXPERIMENTAL
Intervention: Women after pre-eclampsia
Number of subjects: 0
Study 38443087 — intervention group
Group type: COMPARATOR
Intervention: Women after normotensive pregnancy
Number of subjects: 0
Study 38443130 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel
Number of subjects: 1104
Study 38443130 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 1104
Study 38443130 — intervention group
Group type: COMPARATOR
Intervention: Dyad gels (three additional arms in phase 2)
Number of subjects: 1104
Study 38443333 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg orally, twice daily), Bevacizumab biosimilar FKB238 (15 mg/kg intravenously, once every 3 weeks), Durvalumab (1.12 g intravenously, once every 3 weeks)
Number of subjects: 74
Study 38443354 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant monotherapy for 8 weeks
Number of subjects: 135
Study 38443354 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical functional connectivity (FC) score
Number of subjects: 135
Study 38443354 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication analysis in independent sample (n = 74)
Number of subjects: 135
Study 38443427 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-personalised dietary advice
Number of subjects: 148
Study 38443427 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-personalised dietary advice via a self-guided app and wearable device
Number of subjects: 148
Study 38443427 — intervention group
Group type: COMPARATOR
Intervention: Control arm: standard care (NICE guidelines)
Number of subjects: 148
Study 38443648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 98
Study 38443648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 38443660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 388
Study 38443693 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 36
Study 38443722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enhanced MRI (OE-MRI)
Number of subjects: 15
Study 38443835 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening for COPD among hospitalized patients in contact with hospital social nurses.
Number of subjects: 0
Study 38443835 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical examination including spirometry and interviews regarding risk factors, socioeconomic conditions, and respiratory symptoms.
Number of subjects: 0
Study 38443835 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year follow-up assessment incorporating baseline data and register data.
Number of subjects: 0
Study 38443858 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD self-management application on smartphone and smartwatch for 6 months
Number of subjects: 34
Study 38443879 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.9 mm Narrow Diameter Implants (Ti-Zr alloy)
Number of subjects: 40
Study 38443879 — intervention group
Group type: COMPARATOR
Intervention: 3.3 mm Control Group Implants
Number of subjects: 40
Study 38443944 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (physical-cognitive exercise 3 days/week, 3 months)
Number of subjects: 92
Study 38443944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (diet + physical-cognitive exercise)
Number of subjects: 92
Study 38443944 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group (intermittent fasting 2 days/week, 3 months)
Number of subjects: 92
Study 38443944 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group and Combined group
Number of subjects: 92
Study 38443944 — intervention group
Group type: EXPERIMENTAL
Intervention: All three intervention groups (diet, exercise, combined)
Number of subjects: 92
Study 38443957 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered at-home lung ultrasound (SAAH-LUS) with remote teleguidance
Number of subjects: 18
Study 38443957 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote teleguidance by a physician
Number of subjects: 18
Study 38443989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated bottled water (0.7 mg/L F)
Number of subjects: 200
Study 38443989 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated bottled water
Number of subjects: 200
Study 38443992 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (Confident, Active, and Happy Youth)
Number of subjects: 21
Study 38444034 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX combined with TNF-α blocker certolizumab pegol (arm CZP)
Number of subjects: 152
Study 38444034 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX combined with IL-6R blocker tocilizumab (arm TCZ)
Number of subjects: 152
Study 38444034 — intervention group
Group type: COMPARATOR
Intervention: MTX combined with prednisolone (arm ACT)
Number of subjects: 152
Study 38444034 — intervention group
Group type: COMPARATOR
Intervention: MTX combined with CTLA-4Ig abatacept (arm ABA)
Number of subjects: 152
Study 38444034 — intervention group
Group type: COMPARATOR
Intervention: Baseline urinary eicosanoid levels
Number of subjects: 152
Study 38444034 — intervention group
Group type: COMPARATOR
Intervention: Urinary eicosanoid levels
Number of subjects: 152
Study 38444064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotics (5 billion colony-forming units each)
Number of subjects: 72
Study 38444064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 38444312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-closed loop (HCL) therapy from diagnosis of T1D
Number of subjects: 51
Study 38444312 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 51
Study 38444316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop Systems
Number of subjects: 0
Study 38444429 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells (RJMty19)
Number of subjects: 12
Study 38444429 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells (RJMty19) at dose level 1 (DL1)
Number of subjects: 12
Study 38444429 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells (RJMty19) at dose level 3 (DL3)
Number of subjects: 12
Study 38444429 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells (RJMty19) at dose level 4 (DL4)
Number of subjects: 12
Study 38444519 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily prolonged-release tacrolimus (Envarsus) for 4 weeks
Number of subjects: 0
Study 38444519 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 38444629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG)
Number of subjects: 0
Study 38444629 — intervention group
Group type: COMPARATOR
Intervention: Injectable glucagon (IG)
Number of subjects: 0
Study 38444861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC) vaccination combined with carboplatin/paclitaxel chemotherapy
Number of subjects: 7
Study 38444861 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel chemotherapy
Number of subjects: 7
Study 38444875 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (24 weeks)
Number of subjects: 60
Study 38444875 — intervention group
Group type: COMPARATOR
Intervention: Usual care (24 weeks)
Number of subjects: 60
Study 38445250 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-structure culturally tailored healthy eating text messages for 2 months, reinforced for 2 subsequent months.
Number of subjects: 75
Study 38445250 — intervention group
Group type: COMPARATOR
Intervention: Surface-level messages based on USDA MyPlate in Spanish (control group).
Number of subjects: 75
Study 38445295 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg
Number of subjects: 17
Study 38445314 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized home-based rehabilitation intervention
Number of subjects: 60
Study 38445317 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone 8 mg (Group 2)
Number of subjects: 37
Study 38445317 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Group 1)
Number of subjects: 37
Study 38445382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 24 International Units prior to each session of psychotherapy
Number of subjects: 23
Study 38445382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 38445434 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 50
Study 38445434 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 50
Study 38445445 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus the STUPP regimen
Number of subjects: 33
Study 38445452 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting decision trees algorithm using all available variables
Number of subjects: 76457
Study 38445452 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting decision trees algorithm using only preoperative variables
Number of subjects: 76457
Study 38445452 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting decision trees algorithm with top 40 features
Number of subjects: 76457
Study 38445452 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting decision trees algorithm with top 10 features
Number of subjects: 76457
Study 38445452 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models with only preoperative variables or only important predictors
Number of subjects: 76457
Study 38445487 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression-only CPR
Number of subjects: 1250
Study 38445487 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 1250
Study 38445499 — intervention group
Group type: EXPERIMENTAL
Intervention: PWR trajectory cluster α (45 patients, 18.3%)
Number of subjects: 246
Study 38445499 — intervention group
Group type: EXPERIMENTAL
Intervention: PWR trajectory cluster β (105 patients, 42.7%)
Number of subjects: 246
Study 38445499 — intervention group
Group type: EXPERIMENTAL
Intervention: PWR trajectory cluster γ (96 patients, 39.0%)
Number of subjects: 246
Study 38445521 — intervention group
Group type: EXPERIMENTAL
Intervention: SEBE-HCNNSS scale
Number of subjects: 177
Study 38445541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiperstat 5 mg once daily
Number of subjects: 16
Study 38445541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 38445651 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg low-dose melatonin administered 3 hours before the measured DLMO (measured DLMO group, n = 20)
Number of subjects: 40
Study 38445651 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg low-dose melatonin administered 5 hours before sleep-onset time per actigraphy (estimated DLMO group, n = 20)
Number of subjects: 40
Study 38445651 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (evening dim light and time in bed scheduling)
Number of subjects: 40
Study 38445744 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recall period
Number of subjects: 1692
Study 38445744 — intervention group
Group type: COMPARATOR
Intervention: 7-day recall period
Number of subjects: 1692
Study 38445914 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Number of subjects: 90
Study 38445914 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and nab-paclitaxel
Number of subjects: 90
Study 38445950 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity care strategy of guideline-directed medical therapy up-titration
Number of subjects: 1072
Study 38445950 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1072
Study 38445964 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly dordaviprone
Number of subjects: 0
Study 38445964 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly dordaviprone
Number of subjects: 0
Study 38445964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38446022 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary antegrade wiring strategy
Number of subjects: 13563
Study 38446275 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab (5 or 15 mg/kg intravenously every 4 weeks, or 300 or 450 mg subcutaneously every week or every 2 weeks)
Number of subjects: 0
Study 38446275 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab
Number of subjects: 0
Study 38446281 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA 0.1% cationic emulsion (CE)
Number of subjects: 20
Study 38446309 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-g transplant administered once to the colon (LI)
Number of subjects: 186
Study 38446309 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-g transplant administered once to the duodenum (SI)
Number of subjects: 186
Study 38446309 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-g transplant administered twice to the distal duodenum (repeated SI)
Number of subjects: 186
Study 38446316 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food, plant-based diet (WFPB) for 8 weeks
Number of subjects: 32
Study 38446336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)
Number of subjects: 0
Study 38446336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/vilanterol (VI)
Number of subjects: 0
Study 38446336 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC)/vilanterol (VI)
Number of subjects: 0
Study 38446336 — intervention group
Group type: COMPARATOR
Intervention: ICS-containing treatments
Number of subjects: 0
Study 38446336 — intervention group
Group type: COMPARATOR
Intervention: Non-ICS containing treatments
Number of subjects: 0
Study 38446341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (mean dose 262.5 mg/day)
Number of subjects: 42
Study 38446353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu-TLX591 monoclonal antibody (177 Lu-DOTA-rosopatamab) dosed from 1.01-2.85 GBq, 14 days apart
Number of subjects: 18